Role of tumor-associated macrophages in human malignancies: friend or foe?

Pathology International

Volumn 66, Issue 9, 2016, Pages 491-505

  Takeya, Motohiro ^a   Komohara, Yoshihiro ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

human malignant tumors; immunohistochemistry; M1 M2 macrophage subtypes; tumor associated macrophages

Indexed keywords

B CELL LYMPHOMA; BILE DUCT CARCINOMA; BLADDER CARCINOMA; BREAST CANCER; CANCER TISSUE; COLORECTAL CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GLIOMA; HODGKIN DISEASE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MACROPHAGE; MACROPHAGE FUNCTION; MACROPHAGE POLARIZATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOCYTE; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER; T CELL LYMPHOMA; THYROID CANCER; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

HUMANS; MACROPHAGES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84991311768     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12440     Document Type: Review

References (150)

1. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002; 196: 254–5.
2. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605–12.
3. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014; 105: 1–8.
4. Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta 1865; 2016: 23–34.
5. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71–8.
6. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549–55.
7. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol 1993; 24: 534–9.
8. Ginhoux F, Greter M, Leboeuf M et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330: 841–5.
9. van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. J Exp Med 1968; 128: 415–35.
10. Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One 2011; 6 :e23902
11. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166–73.
12. Murray PJ, Allen JE, Biswas SK et al. Macophage activation and polarization: Nomenclature and experimental guidelines. Immunity 2014; 41: 14–20.
13. Doyle AG, Herbein G, Montaner LJ et al. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur J Immunol 1994; 24: 1441–5.
14. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677–86.
15. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958–69.
16. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: Regulation by distinct molecular mechanisms. J Immunol 2008; 180: 2011–17.
17. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol 2009; 27: 451–83.
18. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014; 6: 13.
19. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423–37.
20. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008; 222: 155–61.
21. Noy R, Pollard JW. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014; 41: 49–61.
22. Hasita H, Komohara Y, Okabe H et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010; 101: 1913–19.
23. Raggi C, Mousa HS, Correnti M, Sica A, Invernizzi P. Cancer stem cells and tumor-associated macrophages: A roadmap for multitargeting strategies. Oncogene 2016; 35: 671–82.
24. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer 2014; 14: 736–46.
25. Komohara Y, Horlad H, Ohnishi K et al. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci 2012; 103: 2165–72.
26. Lee H, Deng J, Kujawski M et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010; 16: 1421–8.
27. Kitamura T, Qian BZ, Soong D et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med 2015; 212: 1043–59.
28. Deng J, Liu Y, Lee H et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 2012; 21: 642–54.
29. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625–9.
30. Toi M, Ueno T, Matsumoto H et al. Clinical significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 1999; 5: 1131–7.
31. Valković T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjić N. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 2002; 440: 583–8.
32. Bolat F, Kayaselcuk F, Nursal TZ, Yagmurdur MC, Bal N, Demirhan B. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: Correlations with prognostic parameters. J Exp Clin Cancer Res 2006; 25: 365–72.
33. Yuan ZY, Luo RZ, Peng RJ, Wang SS, Xue C. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco Targets Ther 2014; 7: 1475–80.
34. Sousa S, Brion R, Lintunen M et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res 2015; 17: 101.
35. Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012; 12: 306.
36. Ch'ng ES, Tuan Sharif SE, Jaafar H. In human invasive breast ductal carcinoma, tumor stromal macrophages and tumor nest macrophages have distinct relationships with clinicopathological parameters and tumor angiogenesis. Virchows Arch 2013; 462: 257–67.
37. Chung FT, Lee KY, Wang CW et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer 2012; 131: E227–35.
38. Dai F, Liu L, Che G et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010; 10: 220.
39. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009; 33: 118–26.
40. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 2010; 10: 323.
41. Ohtaki Y, Ishii G, Nagai K et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol 2010; 5: 1507–15.
42. Hirayama S, Ishii G, Nagai K et al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: Possible contribution of CD204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol 2012; 7: 1790–7.
43. + cells predict postoperative recurrence in non-small-cell lung cancer patients. J Thorac Oncol 2014; 9: 179–88.
44. Takahashi A, Ishii G, Kinoshita T et al. Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung. J Cancer Res Clin Oncol 2013; 139: 1869–78.
45. Zhu XD, Zhang JB, Zhuang PY et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008; 26: 2707–16.
46. Ding T, Xu J, Wang F et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 2009; 40: 381–9.
47. Kong LQ, Zhu XD, Xu HX et al. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One 2013; 8 :e59771
48. Li YW, Qiu SJ, Fan J et al. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol 2009; 135: 439–49.
49. + M1-like macrophages promote motility of HCC cells via NF-κB/FAK pathway. Cancer Lett 2014; 345: 91–9.
50. Edin S, Wikberg ML, Oldenborg PA, Palmqvist R. Macrophages: Good guys in colorectal cancer. Oncoimmunology 2013; 2 :e23038
51. Edin S, Wikberg ML, Dahlin AM et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012; 7 :e47045
52. Kang JC, Chen JS, Lee CH, Chang JJ, Shieh YS. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol 2010; 102: 242–8.
53. Ohtani H, Naito Y, Saito K, Nagura H. Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: A possible antitumor immunity? Lab Invest 1997; 77: 231–41.
54. Shabo I, Olsson H, Sun XF, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer 2009; 125: 1826–31.
55. Chang WJ, Du Y, Zhao X, Ma LY, Cao GW. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol 2014; 20: 4586–96.
56. Ishigami S, Natsugoe S, Tokuda K et al. Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res 2003; 23: 4079–83.
57. Pantano F, Berti P, Guida FM et al. The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. J Cell Mol Med 2013; 17: 1415–21.
58. Lin CN, Wang CJ, Chao YJ, Lai MD, Shan YS. The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC Cancer 2015; 15: 128.
59. Erkan M, Hausmann S, Michalski CW et al. The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 2012; 9: 454–67.
60. Kurahara H, Shinchi H, Mataki Y et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011; 167: e211–19.
61. Yoshikawa K, Mitsunaga S, Kinoshita T et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci 2012; 103: 2012–20.
62. Hou YC, Chao YJ, Tung HL, Wang HC, Shan YS. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer 2014; 120: 2766–77.
63. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348: 9–17.
64. Nonomura N, Takayama H, Nakayama M et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 2011; 107: 1918–22.
65. Takayama H, Nonomura N, Nishimura K et al. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer. BJU Int 2009; 103: 470–4.
66. Gollapudi K, Galet C, Grogan T et al. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res 2013; 3: 523–9.
67. Fujii T, Shimada K, Asai O et al. Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology 2013; 80: 119–26.
68. Herrmann G, Schumm-Draeger PM, Müller C et al. T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J Cancer Res Clin Oncol 1994; 120: 651–6.
69. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 2008; 15: 1069–74.
70. Qing W, Fang WY, Ye L et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 2012; 22: 905–10.
71. Cunha LL, Morari EC, Guihen AC et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2012; 77: 918–25.
72. Subimerb C, Pinlaor S, Khuntikeo N et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol Med Rep 2010; 3: 597–605.
73. + monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol 2010; 161: 471–79.
74. Thanee M, Loilome W, Techasen A et al. Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis. Asian Pac J Cancer Prev 2015; 16: 3043–50.
75. Techasen A, Loilome W, Namwat N, Dokduang H, Jongthawin J, Yongvanit P. Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells. Asian Pac J Cancer Prev Suppl 2012; 13: 115–8.
76. Santoni M, Massari F, Amantini C et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2013; 62: 1757–68.
77. Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal cell carcinoma: The role of tumor-associated macrophages. Int J Urol 2009; 16: 801–7.
78. Dannenmann SR, Thielicke J, Stöckli M et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013; 2 :e23562
79. Komohara Y, Hasita H, Ohnishi K et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011; 102: 1424–31.
80. Xu L, Zhu Y, Chen L et al. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol 2014; 21: 3142–50.
81. Komohara Y, Morita T, Annan DA et al. The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res 2015; 3: 999–1007.
82. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000; 7: 263–9.
83. Chen WT, Hung WC, Kang WY et al. Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1α expression, and tumor angiogenesis. APMIS 2009; 117: 176–84.
84. Ayari C, LaRue H, Hovington H et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol 2009; 55: 1386–95.
85. Takayama H, Nishimura K, Tsujimura A et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009; 181: 1894–900.
86. + tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder. Oncotarget 2015; 6: 20204–14.
87. Salvesen HB, Akslen LA. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999; 84: 538–43.
88. Soeda S, Nakamura N, Ozeki T et al. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol 2008; 109: 122–8.
89. Hashimoto I, Kodama J, Seki N et al. Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res 2000; 20: 4853–6.
90. Espinosa I, José Carnicer M, Catasus L et al. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: Tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am J Surg Pathol 2010; 34: 1708–14.
91. Takaishi K, Komohara Y, Tashiro H et al. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci 2010; 101: 2128–36.
92. Lan C, Huang X, Lin S et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat 2013; 12: 259–67.
93. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009; 59: 300–5.
94. Zhang M, He Y, Sun X et al. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res 2014; 7: 19.
95. Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron 2011; 4: 361–75.
96. Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG, Gorter A. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-α, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer 2007; 109: 556–65.
97. Hammes LS, Tekmal RR, Naud P et al. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression—Clinicopathological correlation. Gynecol Oncol 2007; 105: 157–65.
98. Ding H, Cai J, Mao M et al. Tumor-associated macrophages induce lymphangiogenesis in cervical cancer via interaction with tumor cells. APMIS 2014; 122: 1059–69.
99. Petrillo M, Zannoni GF, Martinelli E et al. Polarisation of tumor-associated macrophages toward M2 phenotype correlates with poor response to chemoradiation and reduced survival in patients with locally advanced cervical cancer. PLoS One 2015; 10 :e0136654
100. Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: An immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One 2013; 8 :e80908
101. Guo SJ, Lin DM, Li J et al. Tumor-associated macrophages and CD3-ζ expression of tumor-infiltrating lymphocytes in human esophageal squamous-cell carcinoma. Dis Esophagus 2007; 20: 107–16.
102. Shigeoka M, Urakawa N, Nakamura T et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 2013; 104: 1112–9.
103. Cao W, Peters JH, Nieman D, Sharma M, Watson T, Yu J. Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro. Br J Cancer 2015; 113: 738–46.
104. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15–24.
105. Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 1997; 93: 518–27.
106. Sielska M, Przanowski P, Wylot B et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J Pathol 2013; 230: 310–21.
107. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 1989; 169: 1449–59.
108. Lawson LJ, Perry VH, Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 1992; 48: 405–15.
109. Hirano H, Tanioka K, Yokoyama S, Akiyama S, Kuratsu J. Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme. J Neurosurg 2001; 95: 89–95.
110. Jenny B, Harrison JA, Baetens D et al. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol 2006; 209: 34–43.
111. Coniglio SJ, Eugenin E, Dobrenis K et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 2012; 18: 519–27.
112. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 1996; 92: 288–93.
113. Bröcker EB, Zwadlo G, Holzmann B et al. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 1988; 41: 562–7.
114. Varney ML, Johansson SL, Singh RK. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: Role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 2005; 15: 417–25.
115. Jensen TO, Schmidt H, Møller HJ et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009; 27: 3330–7.
116. Shi L, Lei D, Ma C et al. Clinicopathological implications of tumour-associated macrophages and vascularization in sinonasal melanoma. J Int Med Res 2010; 38: 1276–86.
117. Bronkhorst IH, Ly LV, Jordanova ES et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 2011; 52: 643–50.
118. Coppleson LW, Rappaport H, Strum SB, Rose J. Analysis of the Rye classification of Hodgkin's disease. The prognostic significance of cellular composition. J Natl Cancer Inst 1973; 51: 379–90.
119. Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875–85.
120. Zaki MA, Wada N, Ikeda J et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011; 459: 361–6.
121. Tan KL, Scott DW, Hong F et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial. Blood 2012; 120: 3280–7.
122. Klein JL, Nguyen TT, Bien-Willner GA et al. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol 2014; 141: 381–7.
123. Koh YW, Park CS, Yoon DH, Suh C, Huh J. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLoS One 2014; 9 :e87066
124. Azambuja D, Natkunam Y, Biasoli I et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012; 23: 736–42.
125. Barros MH, Segges P, Vera-Lozada G, Hassan R, Niedobitek G. Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival. PLoS One 2015; 10 :e0124531
126. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–69.
127. Farinha P, Masoudi H, Skinnider BF et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169–74.
128. Canioni D, Salles G, Mounier N et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440–6.
129. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppä S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13: 5784–9.
130. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in follicular lymphoma: Importance of markers of immune response. Leuk Lymphoma 2007; 48: 2403–11.
131. Cai QC, Liao H, Lin SX et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol 2012; 29: 2317–22.
132. Wada N, Zaki MA, Hori Y et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: A study of the Osaka Lymphoma Study Group. Histopathology 2012; 60: 313–9.
133. Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson PO. Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 2008; 58: 529–32.
134. Marchesi F, Cirillo M, Bianchi A et al. High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 2015; 33: 110–2.
135. Nam SJ, Go H, Paik JH et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2014; 55: 2466–76.
136. Leidi M, Gotti E, Bologna L et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009; 182: 4415–22.
137. Kridel R, Xerri L, Gelas-Dore B et al. The prognostic impact of CD163-positive macrophages in follicular lymphoma: A study from the BC Cancer Agency and the Lymphoma Study Association. Clin Cancer Res 2015; 21: 3428–35.
138. + tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci 2013; 104: 945–51.
139. Saito Y, Komohara Y, Niino D et al. Role of CD204-positive tumor-associated macrophages in adult T-cell leukemia/lymphoma. J Clin Exp Hematop 2014; 54: 59–65.
140. Niino D, Komohara Y, Murayama T et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010; 60: 278–83.
141. + cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 2012; 68: 45–51.
142. Lin ZX, Bai B, Cai QC et al. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med Oncol 2012; 29: 3522–8.
143. Wang H, Li P, Wang L et al. High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2015; 94: 1535–44.
144. Shigeoka M, Urakawa N, Nishio M et al. Cyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinoma. Cancer Med 2014; 4: 437–46.
145. Philippidis P, Mason JC, Evans BJ et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte–macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 2004; 94: 119–26.
146. Ohnishi K, Komohara Y, Fujiwara Y et al. Suppression of TLR4-mediated inflammatory response by macrophage class A scavenger receptor (CD204). Biochem Biophys Res Commun 2011; 411: 516–22.
147. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 2016; 99: 180–5.
148. Mantovani A, Allevena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015; 212: 435–55.
149. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: Enabling diversity with identity. Nat Rev Immunol 2011; 11: 750–61.
150. Fujiwara Y, Komohara Y, Ikeda T, Takeya M. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci 2011; 102: 206–11.